Form 4: Sarepta Therapeutics Executive Dallan Murray Reports Stock Sale to Cover Tax Obligations

Dallan Murray, Chief Customer Officer of Sarepta Therapeutics, sold shares to cover tax obligations related to vesting restricted stock units.

Summary

• On March 4, 2025, Dallan Murray, Chief Customer Officer of Sarepta Therapeutics, sold 1,685 shares of common stock at a price of $101.34 per share.
• The sale was executed to satisfy tax withholding obligations related to the vesting of restricted stock units granted on March 3, 2021.
• Following the transaction, Murray directly owns 19,821 shares of Sarepta Therapeutics common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction related to tax obligations, not indicative of a major positive or negative event for the company.

Industry Context

This is a routine transaction; executives often sell shares to cover tax obligations when restricted stock units vest. It doesn't necessarily indicate a lack of confidence in the company.

Comparison to Industry Standards

• Similar transactions are common among executives at publicly traded companies, including those in the biotechnology sector like Amgen, Biogen, and Vertex Pharmaceuticals.
• These companies' executives regularly file Form 4s to report similar sales related to stock options or restricted stock units.

Stakeholder Impact

• The sale has a minimal impact on shareholders as it's a small percentage of the total outstanding shares.
• Employees may be interested in the transaction as it relates to the vesting of restricted stock units, a common form of compensation.

Key Dates